Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
← catalyst calendarNCT05040373 · readout in 1,515 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
10estimated
Sites
7
Countries
France, Germany, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-08-01 | actual | When the study began enrolling |
| Primary completion | 2030-10-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-10-12 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hereditary Transthyretin-mediated (hATTR) Amyloidosis
- Polyneuropathy
Primary outcome
what the primary-completion date above is the date OFPrevalence of Major Congenital Malformations
measured From 12 weeks prior to last dose of patisiran through one year after birth (Up to 21 months)
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed